Fast Company on MSN13d
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsSpravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Boing Boing on MSN11d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
Johnson & Johnson Q4 adjusted EPS of $2.04 ... (ciltacabtagene autoleucel), Tremfya (guselkumab), and Spravato (esketamine), driven by continued strong share gains and market growth.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback